Neurocrine Biosciences, Inc. (NBIX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,046 | 1,134 | 1,489 | 1,887 | 2,355 | 2,861 | 3,374 | 3,901 |
| Operating profit | $m | 619 | 789 | ||||||
| Net profit | $m | 407 | 90 | 155 | 250 | 341 | 479 | 706 | 673 |
| EPS reported | $ | 4.67 | 6.82 | ||||||
| Operating cashflow per share | $ | 7.87 | 8.89 | ||||||
| Capex per share | $ | 0.34 | 0.27 | ||||||
| FCF per share | $ | 7.52 | 8.62 | ||||||
| Free cash flow | $m | 749 | 870 | ||||||
| Net debt | $m | -1,480 | -390 | ||||||
| Book value equity | $m | 3,253 | 3,694 | ||||||
| Book value per share | $ | 31.74 | 35.45 | ||||||
| Number of shares | m | 102.5 | 104.2 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 30.37 | 20.29 | ||||||
| P/B LTM | x | 4.34 | 3.82 | ||||||
| P/S LTM | x | 4.93 | 4.18 | ||||||
| P/FCF LTM | x | 18.85 | 16.21 | ||||||
| EV/EBITDA LTM | x | 20.72 | 15.05 | ||||||
| EV/Sales LTM | x | 4.83 | 4.57 | ||||||
| Earnings Yield LTM | % | +3.29% | +4.93% | ||||||
| FCF Yield | % | +5.31% | +6.17% | ||||||
| Quality | |||||||||
| ROE | % | +14.71% | +21.13% | ||||||
| ROIC | % | +10.80% | +13.20% | ||||||
| Operating margin | % | +21.64% | +23.38% | ||||||
| Gross margin | % | +98.18% | +97.97% | ||||||
| FCF/Sales | % | +26.17% | +25.80% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +41.95% | +107.29% | ||||||
| Sales Growth YoY | % | +21.45% | +43.25% | ||||||
| Net Income Growth YoY | % | +40.23% | +106.71% | ||||||
| FCF Growth | % | +34.37% | +56.21% | ||||||
| Operating Profit Growth | % | +8.52% | +38.28% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 1.80 | 2.17 | ||||||
| Net Debt/EBITDA | x | -0.45 | 0.08 | ||||||
| EBIT/Net interest | x | 0.00 | 272.03 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.46 | -0.11 | ||||||
| Gross debt/equity | x | 0.13 | 0.11 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Neurocrine Biosciences, Inc. (NBIX)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free